Oral contraceptives (OCs) are associated with a small increase in premenopausal breast cancer risk, especially in parous women who use them for 4 or more years before a first full-term pregnancy, according to a new meta-analysis.
FDA grants 510(k) clearance to chemiluminescence-based immunoassay
Published: January 10th 2025 | Updated: January 10th 2025The automated chemiluminescence-based immunoassay has received clearance for free testosterone, providing enhanced diagnostic options to a multitude of conditions.
Read More